Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
Conditions: Transthyroxin Amyloidosis Cardiomyopathy Interventions: Drug: YOLT-201 Sponsors: Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
National Registry of Rare Kidney Diseases
Conditions: Adenine Phosphoribosyltransferase Deficiency; AH Amyloidosis; AHL Amyloidosis; AL Amyloidosis; Alport Syndrome; Atypical Hemolytic Uremic Syndrome; Autoimmune Distal Renal Tubular Acidosis; Autosomal Recessive Proximal Renal Tubular Acidosis; Autosomal Recessive Distal Renal Tubular Acidosis; Autosomal Dominant Polycystic Kidney Disease; Autosomal Recessive Polycystic Kidney Disease; Bartter Syndrome; BK Nephropathy; C3 Glomerulopathy With Monoclonal Gammopathy; C3 Glomerulopathy; Calciphylaxis; Crystalglobulinaemia; Crystal-storing Histiocytosis; Cystinosis; Cystinuria; Dense Deposit Disease; Dent Disease; Den...
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
Conditions: Amyloidosis Cardiac; Aortic Stenosis, Severe Sponsors: University Hospital of Ferrara Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis
Conditions: Amyloid; Amyloid Cardiomyopathy Intervention: Diagnostic Test: 18F-florbetaben PET/CT Sponsor: Fondazione Toscana Gabriele Monasterio Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
LOS ANGELES, Sept. 21, 2023— Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the“Company”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Vasculitic Neuropathy; POEMS Syndrome; Multifocal Motor Neuropathy; Charcot-Marie-Tooth; hATTR Amyloidosis; Diabetic Polyneuropathy; Idiopathic Neuropathy; Polyneuropathies Interventions: Other: Validity and reliability of outcome measures in polyneuropathy; Other: Healthy controls Sponsor: Rigshospitalet, Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
